Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 23, 2015Leukemia & lymphoma/Leukemia and lymphomaOpen Access

Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update

View Full Paper
Ask AI
Bookmark
Share

Authors

BCBruce D. ChesonWBWolfram BruggerGDGandhi Damaj

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cheson et al. (2015) studied this question.

synapsesocial.com/papers/6a7068ef26a7f98052dce9bdhttps://doi.org/10.3109/10428194.2015.1099647
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study2012 · 121 citations
  2. 2Efficacy and safety of bendamustine for the treatment of patients with recurring <scp>H</scp>odgkin lymphoma2012 · 63 citations
  3. 3Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group2011 · 376 citations
  4. 4Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkinʼs lymphomas2001 · 102 citations